The Landsteiner Foundation for Blood Transfusion Research (LSBR) has awarded the LSBR Anniversary Grant of € 1.6 million to the HemoTwin-BD consortium. HemoTwin-BD is a nation-wide, multidisciplinary research program aimed at understanding heterogeneity in the laboratory and bleeding phenotype of patients with bleeding disorders. Dr Ferdows Atiq and Dr Ruben Bierings, from the department of Hematology at Erasmus MC, are key members of the collaboration, overseeing the research on von Willebrand disease and von Willebrand Factor cell biology, respectively.
The HemoTwin-BD program brings together large national patient cohorts from the Dutch Hemophilia Treatment Centers (HTCs) and diverse scientific expertise to investigate how genetic variation is translated into distinct proteoforms that shape an individual’s hemostatic system. By combining advanced laboratory research with AI-based modelling, the consortium will develop digital twins to uncover new biological mechanisms underlying bleeding disorders. These insights are expected to contribute to the development of more personalized, effective, and safer treatment strategies. The consortium consists of clinical experts, fundamental researchers, and data scientists and is coordinated by the group of Dr. Maartje van den Biggelaar at Sanquin.
Read more at the LSBR.
Reactie plaatsen
Reacties